A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
The Latest on: Vaccine development
- New strains of hepatitis C found in Africa on December 17, 2018 at 11:36 am
The study could inform hepatitis C vaccine development and assist the World Health Organization's aim of eliminating hepatitis C globally. The largest population study of hepatitis C in Africa has fou... […]
- Research opens door to development of drug or vaccine for late-onset Alzheimer's on December 17, 2018 at 9:11 am
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer's disease, opening the door to development of a drug that could be administered ... […]
- Lyme Disease vaccine candidate enters Phase 2 clinical development on December 17, 2018 at 2:59 am
In a follow-up on the development of Valneva’s Lyme Disease vaccine candidate, VLA15, the company announced today that it is entering Phase 2 Clinical Development. Borrelia burgdorferi ... […]
- Innovations in Predictive 3D Modeling of Live Human Cells, Vaccine Development, Gene Editing, and Targeted Protein Degradation Platforms, 2018 Study - ResearchAndMarkets.com on December 14, 2018 at 11:57 am
DUBLIN--(BUSINESS WIRE)--The "Innovations in Predictive 3D Modeling of Live Human Cells, Vaccine Development, Gene Editing, and Targeted Protein Degradation Platforms" report has been added to Researc... […]
- Pfizer launches late-stage development of 20-valent pneumonia vaccine on December 14, 2018 at 7:35 am
Pfizer (PFE-1.8%) initiates a Phase 3 program for Breakthrough Therapy-tagged PF-06482077, its 20-valent vaccine candidate for the prevention of invasive disease and pneumonia caused by ... […]
via Google News and Bing News